04 Dec 2025
· Regulatory information
Guard Therapeutics Explores Strategic Alternatives
Guard Therapeutics (publ) (“Guard” or the “Company”) today announces that the Board of Directors has resolved to commence an exploratory process regarding strategic alternatives, including identifying potential candidates for a merger or reverse takeover (RTO) of the Company. Guard believes that its listing on Nasdaq First North Growth Market in Stockholm, together with its cash position, may represent significant value for potential counterparties.
Read more
04 Dec 2025
Guard Therapeutics Provides Assessment of Full POINTER Study Results
Guard Therapeutics (public) (“Guard” or “the Company”) today provides an assessment of the full results from the Phase 2b POINTER study evaluating RMC-035 in patients undergoing open-heart surgery. As previously communicated, the study did not meet its primary or key secondary efficacy endpoints, although promising signals were observed with the 30 mg dose level, particularly in reducing acute kidney injury. Given the overall negative outcome of the study, the Company has decided to discontinue all further development of RMC-035.
Read more
26 Oct 2025
· Regulatory information
Guard Therapeutics Announces Top-Line Results from Phase 2b POINTER Study
Guard Therapeutics (publ) today announced top-line results from the company’s Phase 2b POINTER study evaluating the investigational drug candidate RMC-035 as a kidney-protective therapy in patients undergoing open-heart surgery. The study did not meet its primary and key secondary efficacy endpoints.
Read more
17 Oct 2025
Guard Therapeutics to Present Late-Breaking Phase 2b POINTER Results at ASN Kidney Week 2025
Guard Therapeutics (publ) today announced that top-line results from the company’s Phase 2b POINTER study with the investigational drug candidate RMC-035 have been selected for oral presentation on November 6 as a Late-Breaking Clinical Trial at the scientific conference American Society of Nephrology (ASN) Kidney Week 2025 in Houston, TX, USA.
Read more
05 Oct 2025
· Regulatory information
Guard Therapeutics Announces New Positive Efficacy Results from Secondary Analyses of the Phase 2a AKITA Study
Guard Therapeutics (publ) today announced favorable efficacy results from additional analyses of the Phase 2a AKITA study with the investigational drug candidate RMC-035. The previously reported primary results demonstrated a robust improvement in kidney function following open-heart surgery. The new analyses strengthen these findings and show that RMC-035 provides kidney-protective benefits both in patients with and without acute kidney injury, and additionally reduces key biomarkers of kidney damage, including albuminuria, further supporting its kidney-protective potential. Selected results will be presented at the leading U.S. scientific conference ASN Kidney Week 2025.
Read more
11 Sep 2025
Guard Therapeutics announces completion of data collection in Phase 2b POINTER study
Guard Therapeutics (publ) today announced that the last patient in its ongoing Phase 2b clinical trial, POINTER, has successfully completed the final scheduled follow-up visit 90 days after surgery (last patient last visit). The study is evaluating the company’s drug candidate, RMC-035, as a kidney-protective treatment for patients undergoing open-heart surgery.
Read more
28 Aug 2025
Guard Therapeutics presents additional AKITA results at leading U.S. nephrology conference
Guard Therapeutics (publ) today announced that additional results from the Phase 2 AKITA study with the company’s drug candidate RMC-035 will be presented at the scientific conference Kidney Week 2025 organized by the American Society of Nephrology (ASN), in Houston, TX, USA. The new results are based on post hoc analyses of the previously completed and reported study and provide deeper insights into the potential of RMC-035 to preserve kidney function after open-heart surgery.
Read more
22 Aug 2025
Guard Therapeutics to present at upcoming investor conferences
Guard Therapeutics (publ) today announced that the company will present at the following investor conferences ahead of the upcoming readout of the Phase 2b POINTER study:
Read more
21 Aug 2025
· Regulatory information
Guard Therapeutics publishes interim report January–June 2025
The quarter marked a key milestone with the completion of patient recruitment for our Phase 2b POINTER study – ahead of schedule. The positive final safety review reinforces confidence in the trial, underscoring strong momentum and positioning us well for future value creation.
Read more
05 Jun 2025
Guard Therapeutics announces completion of patient enrollment in Phase 2b POINTER study
Guard Therapeutics (publ) today announced that the last patient has been successfully enrolled in the company’s ongoing Phase 2b clinical trial, POINTER, evaluating the drug candidate RMC-035 as a kidney-protective therapy in patients undergoing open-heart surgery.
Read more